Rep. Neugebauer: Market, Not Government, Should Regulate Terrorism Insurance

Humberto Sanchez And Billy House
See more stories about...
Humberto Sanchez and Billy House
Nov. 19, 2013, 7:46 a.m.
2851445810001
What We're Following See More »
BUT HE’S NOT ADVOCATING FOR IT
Grassley Open to Lame Duck Hearings on Garland
14 hours ago
THE LATEST

Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.

Source:
DOWN FROM POST-CONVENTION NUMBERS
Monmouth Has Clinton Up Seven
18 hours ago
THE LATEST

In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.

Source:
DEBATE PREP
Clinton Advisers Talking to Psychologists, Trump Ghostwriter
18 hours ago
THE LATEST

“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”

EPI-PEN PRICES
House Committee Investigating Mylan
21 hours ago
THE LATEST

The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.

Source:
×